Synthetic Biologics to Report 2020 Second Quarter Operational Highlights and Financial Results on August 6, 2020
Synthetic Biologics, Inc. (NYSE American: SYN) will release its operational highlights and financial results for the quarter ended June 30, 2020 on August 6, 2020, followed by a conference call at 4:30 p.m. ET. The company focuses on developing therapeutics leveraging the microbiome to address gastrointestinal diseases. Key candidates include SYN-004, aimed at preventing microbiome damage from antibiotics, SYN-010 for irritable bowel syndrome with constipation, and SYN-020 to treat GI and systemic diseases. More details are available on their website.
- Company plans to report operational highlights and financial results, indicating ongoing activity and transparency.
- Development of innovative therapeutics targeting high unmet needs in gastrointestinal diseases.
- None.
ROCKVILLE, Md., July 29, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended June 30, 2020 on Thursday, August 6, 2020, and to host a conference call the same day at 4:30 p.m. ET. The dial-in information for the call is as follows:
U.S. (toll free): 1-888-347-5280
International: +1-412-902-4280
Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/35797An archived replay of the call will be available for approximately ninety (90) days at the same URL, https://www.webcaster4.com/Webcast/Page/1096/35797 beginning approximately one hour after the call's conclusion.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead clinical candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, C. difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also advancing SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-2020-second-quarter-operational-highlights-and-financial-results-on-august-6-2020-301102511.html
SOURCE Synthetic Biologics, Inc.
FAQ
When will Synthetic Biologics report its Q2 financial results?
What time is the Synthetic Biologics conference call?
What are the main products being developed by Synthetic Biologics?
Where can I find more information about Synthetic Biologics?
